Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trametinib With Docetaxel in KRAS Mutation Positive NSCLC
NCT02642042Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Jul 2016
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trametinib in non-small cell lung cancer (NSCLC), sponsored by National Cancer Institute. Primary endpoint: Objective Response Rate at 3 years. Started Jul 2016; status: active, not recruiting.
02
Drugs
trametinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02642042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02642042.